Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
SKYE 
Skye Bioscience, Inc. Common Stock (SKYE)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
11/05/2025: SKYE (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
7 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $8.27
1 Year Target Price $8.27
| 4 | Strong Buy |
| 3 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -31.79% | Avg. Invested days 25 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 11/05/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 47.41M USD | Price to earnings Ratio - | 1Y Target Price 8.27 |
Price to earnings Ratio - | 1Y Target Price 8.27 | ||
Volume (30-day avg) 7 | Beta 2.66 | 52 Weeks Range 1.14 - 5.90 | Updated Date 11/8/2025 |
52 Weeks Range 1.14 - 5.90 | Updated Date 11/8/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.06 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -40.92% | Return on Equity (TTM) -72.75% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 90920262 | Price to Sales(TTM) - |
Enterprise Value 90920262 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -2.56 | Shares Outstanding 30988420 | Shares Floating 18620012 |
Shares Outstanding 30988420 | Shares Floating 18620012 | ||
Percent Insiders 1.44 | Percent Institutions 65.94 |
Upturn AI SWOT
Skye Bioscience, Inc. Common Stock
Company Overview
History and Background
Skye Bioscience, Inc. is a biopharmaceutical company focused on developing novel cannabinoid-based therapies to address diseases with significant unmet needs. They focus on glaucoma and other conditions. Founded to advance cannabinoid science.
Core Business Areas
- Pharmaceutical Development: Focus on developing cannabinoid-derived therapeutics for glaucoma and other ophthalmic conditions.
- Preclinical and Clinical Research: Conducting research to evaluate the safety and efficacy of their drug candidates.
Leadership and Structure
Leadership team comprises experienced pharmaceutical executives and scientists. The structure is typically organized around research and development, clinical operations, and corporate functions.
Top Products and Market Share
Key Offerings
- SBI-100 Ophthalmic Emulsion: A novel formulation of a synthetic cannabinoid derivative being developed for the treatment of glaucoma. Early clinical trials show promise in reducing intraocular pressure (IOP). Competitors include large pharmaceutical companies with established glaucoma treatments like Allergan (now AbbVie) and Novartis. Market share data is not yet available as it is still in development.
Market Dynamics
Industry Overview
The pharmaceutical industry is highly competitive and heavily regulated. The glaucoma treatment market is substantial and growing due to an aging population and increasing prevalence of the disease.
Positioning
Skye Bioscience is positioning itself as an innovator in cannabinoid-based therapies for ophthalmic diseases, aiming to offer a novel treatment option for glaucoma patients.
Total Addressable Market (TAM)
The global glaucoma market is estimated to be worth billions of dollars annually. Skye Bioscience aims to capture a share of this market by offering a differentiated product with potentially improved efficacy or safety profiles.
Upturn SWOT Analysis
Strengths
- Novel cannabinoid-based therapeutic approach
- Strong intellectual property portfolio
- Experienced management team
- Promising early clinical trial results
Weaknesses
- Limited financial resources
- Dependence on successful clinical trial outcomes
- High regulatory hurdles
- Early stage of development
Opportunities
- Partnerships with larger pharmaceutical companies
- Expansion into other ophthalmic indications
- Growing acceptance of cannabinoid-based therapies
- Potential for breakthrough therapy designation
Threats
- Competition from established glaucoma treatments
- Clinical trial failures
- Regulatory delays or rejection
- Changes in reimbursement policies
Competitors and Market Share
Key Competitors
- AbbVie (ABBV)
- Novartis (NVS)
- Aerie Pharmaceuticals (ARIE) - Acquired by Alcon
- Alcon (ALC)
Competitive Landscape
Skye Bioscience faces intense competition from established pharmaceutical companies with existing glaucoma treatments. Its success depends on demonstrating superior efficacy or safety with its cannabinoid-based approach.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is based on R&D progress and market capitalization fluctuation.
Future Projections: Future growth depends on successful clinical trials, regulatory approvals, and commercialization of SBI-100. Analyst projections will be based on the company's clinical trial milestones.
Recent Initiatives: Focusing on clinical trials for SBI-100 and seeking potential partnerships.
Summary
Skye Bioscience is a high-risk, high-reward biopharmaceutical company focused on developing cannabinoid-based therapies for glaucoma. Early clinical results are promising, but the company faces significant regulatory and competitive hurdles. The company needs successful clinical trials and potential partnerships to be commercially viable. Failure of trials, or not enough investment in the company are threats it needs to avoid.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company SEC Filings
- Company Website
- Analyst Reports
- Industry Reports
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. Investment decisions should be based on thorough research and consultation with a qualified financial advisor. Market data is subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Skye Bioscience, Inc. Common Stock
Exchange NASDAQ | Headquaters San Diego, CA, United States | ||
IPO Launch date 2015-04-02 | President, CEO, Secretary & Director Mr. Punit S. Dhillon B.A. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 16 | Website https://skyebioscience.com |
Full time employees 16 | Website https://skyebioscience.com | ||
Skye Bioscience, Inc., a clinical stage biopharmaceutical company, focuses on developing molecules that modulate G protein-coupled receptors (GPCRs) to treat obesity, overweight, and metabolic diseases. Its lead product candidate is nimacimab, a peripherally restricted negative allosteric modulating antibody targeting cannabinoid receptor 1, a key GPCR involved in metabolic regulation. The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in January 2021. The company is headquartered in San Diego, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.